Immunovant To Present at the 9th Annual SVB Leerink Global Healthcare Conference
NEW YORK, February 10, 2020 / PRNewswire Immunovant, Inc. (NASDAQ: IMVT) a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27 in New York City.
9th Annual Global Healthcare Conference
Date: Tuesday, February 25th
Time: 3:00pm Eastern Time
Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com
About Immunovant, Inc.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
John Strumbos, Ph.D., MBA
Vice President, Finance